Illinois class action claims that Walgreens failed to warn consumers that one of the high blood pressure medications available from the pharmacy, Valsartan, was a toxic drug containing a suspected carcinogen.
The lawsuit was filed in Cook County Circuit Court on Friday. The lawsuit claims that Walgreens Boots Alliance Inc. materially misrepresented the safety of Valsartan, which had been recalled by the FDA due to the presence of probable carcinogen N-nitrosodimethylamine, or NDMA, and N-nitrosodiethylamine, or NDEA, a suspected human and known animal carcinogen.
Plaintiffs claim that Walgreens was aware that the product was toxic, but failed to warn consumers, putting them at risk.
Harry Shanov, plaintiff, said that if he, himself, or other members of the class action knew of the alleged health risks associated with Valsartan, they would have not purchased the product.
According to the complaint, plaintiff consumers believed that they were purchasing Valsartan “and only Valsartan, as opposed to Valsartan that contained elevated and unsafe levels of NDMA and NDEA.”
Shanov says that his prescription was also misleading. Based on the label of his prescription, he believed that Valsartan did not pose any “undisclosed increased risk” of health risks.